Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 3/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12257425 | 0.92 | ADORA1 (0.47) | ADORA1ADORA3MAOBADORA2AGLA | |
| SCHEMBL12257462 | 0.91 | ADORA2A (0.49) | ADORA1ADORA3MAOBADORA2AADORA2B | |
| SCHEMBL12257518 | 0.91 | ADORA1 (0.49) | ADORA1ADORA3MAOBADORA2AGLA | |
| SCHEMBL12256472 | 0.83 | ADORA2A (0.45) | ADORA1ADORA3MAOBADORA2AADORA2B | |
| SCHEMBL12259507 | 0.83 | ADORA2B (0.46) | ADORA1ADORA3MAOBADORA2AADORA2B | |
| SCHEMBL12257272 | 0.83 | ADORA2A (0.44) | ADORA1ADORA3MAOBADORA2AADORA2B | |
| SCHEMBL12259553 | 0.83 | ADORA1 (0.57) | ADORA1MAOBADORA2AGLAADORA2B | |
| SCHEMBL12257531 | 0.83 | KDM4E (0.51) | ADORA1ADORA2AGLAADORA2BBLM | |
| SCHEMBL4949594 | 0.82 | ADORA1 (0.46) | ADORA1ADORA3MAOBADORA2AGLA | |
| SCHEMBL8184575 | 0.82 | ADORA2A (0.54) | ADORA1ADORA3MAOBADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044061-B2 | Parkinson's disease, catalepsy, dystonia, dyskinetic syndrome, restless legs syndrome, migraine, pain, dementia, neurodegenerative disorders, alcohol withdrawal and/or ischemic conditions such as e.g. stroke or cardiac ischemia. | UCB PHARMA GMBH (DE) | 2011-10-25 | — | — | US | disclosed |
| US-20080221134-A1 | 8-ALKYNYLXANTHINES AND DERIVATIVES | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAET BONN (DE) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221134-A1 | 8-ALKYNYLXANTHINES AND DERIVATIVES | SLC6A3, PARK7, SLC18A2 | ADORA1 314/4885ADORA3 248/4885MAOB 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.